SS Innovations International (SSII) 10-K 3 Nov 22 2021 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2021	Nov. 01, 2022	Jun. 30, 2021
Document Information Line Items
Entity Registrant Name	AVRA MEDICAL ROBOTICS, INC
Document Type	10-K
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		39,197,099
Entity Public Float			$ 0
Amendment Flag	false
Entity Central Index Key	0001676163
Entity Current Reporting Status	No
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
ICFR Auditor Attestation Flag	false
Entity File Number	333-216054
Entity Incorporation, State or Country Code	FL
Entity Tax Identification Number	47-3478854
Entity Address, Address Line One	3259 Progress Drive
Entity Address, Address Line Two	Suite 114
Entity Address, City or Town	Orlando
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	32826
City Area Code	(407)
Local Phone Number	956-2250
Entity Interactive Data Current	Yes
Auditor Name	BF Borgers CPA PC
Auditor Firm ID	5041
Auditor Location	Lakewood, CO
Document Annual Report	true
Document Transition Report	false

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2021	Dec. 31, 2020
CURRENT ASSETS:
Cash and cash equivalents	$ 405,774	$ 160,709
Other prepaid expenses and deposit	2,291	2,290
Total Current Assets	408,065	162,999
EQUIPMENT:
Equipment	98,592	98,592
Accumulated depreciation	(78,050)	(60,385)
Total Equipment, net	20,542	38,207
INVESTMENT: Investment in Avra Air LLC		115,542
OTHER ASSETS:
Website	36,122	36,122
Accumulated amortization	(36,122)	(35,000)
Total Other Assets, net		1,122
TOTAL ASSETS	428,607	317,870
CURRENT LIABILITIES:
Accounts payable	124,581	131,719
Accrued compensation		671,500
Accrued expenses	17,700	188,700
Notes payable - related party	145,000	195,000
Promissory notes
Total Current Liabilities	287,281	1,186,919
Commitments and contingencies (see Note 8)
STOCKHOLDERS' DEFICIT:
Preferred stock, 5,000,000 shares authorized, $.0001 par value, none issued or outstanding
Common stock, 100,000,000 shares authorized, $.0001 par value, 37,848,905 and 25,721,971 issued and outstanding at December 31, 2021 and December 31, 2020 respectively	3,785	2,572
Common stock liability, 4,265,295 and 289,697 shares, $.0001 par value at December 31, 2021 and December 31, 2020, respectively	458,519	100,925
Additional paid in capital	8,183,082	6,021,201
Treasury stock	(26,000)
Accumulated deficit	(8,478,060)	(6,993,747)
Total Stockholders' Deficit	141,326	(869,049)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 428,607	$ 317,870

Balance Sheets (Parentheticals)

Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Preferred stock , par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	37,848,905	25,721,971
Common stock, shares outstanding	37,848,905	25,721,971
Common stock liability, shares	4,265,295	289,697
Common stock liability, par value (in Dollars per share)	$ 0.0001	$ 0.0001

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Revenue
OPERATING EXPENSES
Research and Development	1,000	3,000
Compensation Expense	947,237	812,190
General and Administrative	458,801	287,737
Total Operating Expenses	1,407,038	1,102,927
OTHER INCOME AND (EXPENSES)
Gain on forgiveness of PPP Loan		4,630
Investment loss	(77,392)	(25,331)
Interest Earned	118	6
Interest Expense		(1,059)
Total Other Income and (Expenses), net	(77,274)	(21,754)
Loss before income tax taxes	(1,484,313)	(1,124,681)
Provision for Income Tax
NET LOSS	$ (1,484,313)	$ (1,124,681)
Loss per common share - basic and diluted (in Dollars per share)	$ (0.05)	$ (0.05)
Weighted average common shares outstanding - basic and diluted (in Shares)	28,480,973	23,372,299

Statements of Operations (Paren

Statements of Operations (Parentheticals) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Loss per common share - basic and diluted	$ (0.05)	$ (0.05)
Weighted average common shares outstanding - basic and diluted	28,480,973	23,372,299

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
CASH FLOWS OPERATING ACTIVITIES:
Net loss	$ (1,484,313)	$ (1,124,681)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	18,787	37,431
Stock compensation expense	767,237	434,180
Stock issued for services	1,107,500
Investment loss	77,392	25,331
Gain on forgiveness of PPP Loan		(4,630)
Non-cash interest
Changes in operating assets and liabilities:
Other prepaid expenses and deposit		4,000
Accounts payable and accrued expenses	(849,637)	537,829
Net Cash Used in Operating Activities	(363,034)	(90,540)
INVESTING ACTIVITIES:
Investment		(40,000)
Website costs
Equipment acquisition		(4,000)
Investment in Avra Air LLC	38,150
Net Cash Used in Investing Activities	38,150	(44,000)
FINANCING ACTIVITIES:
Proceeds from notes payable related party		130,200
Proceeds from promissory notes		(65,000)
Proceeds from SBA		4,630
Proceeds from private placement	315,200	194,845
Proceeds from exercise of stock options	12,900	2,100
Proceeds from securities offering	267,850
Treasury stock	(26,000)
Net Cash Provided by Financing Activities	569,949	266,775
(DECREASE)/INCREASE IN CASH AND CASH EQUIVALENTS	245,065	132,235
CASH AND CASH EQUIVALENTS - BEGINNING OF YEAR	160,709	28,474
CASH AND CASH EQUIVALENTS - END OF YEAR	405,774	160,709
Supplemental information of non-cash investing and financing activities:
Cash paid for interest		1,059
Cash received for interest	118
Non-cash financing activities:
Equipment acquisition included in accounts payable
Related party note payable converted into common stock	50,000	302,700
Promissory note converted into common stock		45,000
Stock issued for investment acquisition		170,000
Reduction of account payable and equipment	$ 9,543	$ 25,000

Statement of Shareholders_ Defi

Statement of Shareholders’ Deficit - USD ($)	Common Stock	Common Stock to be issued	Additional Paid-In Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2019	$ 2,186	$ 254,564	$ 4,549,058	$ (5,869,066)	$ (1,063,258)
Balance (in Shares) at Dec. 31, 2019	21,857,218	128,909
Stock based compensation expense			412,789		412,789
Stock warrants			29,291		29,291
Stock issued for services	$ 44		195,045		195,089
Stock issued for services (in Shares)	436,023
Exercise of stock options	$ 2		2,098		2,100
Exercise of stock options (in Shares)	21,000
Common stock issuable for services		$ (153,639)	165,088		11,449
Common stock issuable for services (in Shares)		160,788
Conversion of debt to equity	$ 181		302,519		302,700
Conversion of debt to equity (in Shares)	1,810,800
Private Placement	$ 112		194,730		194,842
Private Placement (in Shares)	1,124,708
Purchase of Investment	$ 47		169,953		170,000
Purchase of Investment (in Shares)	472,222
Net loss				(1,124,681)	(1,124,681)
Balance at Dec. 31, 2020	$ 2,572	$ 100,925	6,021,201	(6,993,747)	(869,049)
Balance (in Shares) at Dec. 31, 2020	25,721,971	289,697
Stock based compensation expense	$ 741		862,107		862,849
Stock based compensation expense (in Shares)	7,413,990
Stock issued for services	$ 21		276,676		276,697
Stock issued for services (in Shares)	210,000
Common stock issuable for services		$ 869,668			869,668
Common stock issuable for services (in Shares)		4,745,196
Conversion of debt to equity	$ 38		49,961		50,000
Conversion of debt to equity (in Shares)	384,615
Security Offerings	$ 112		146,161		146,273
Security Offerings (in Shares)	1,120,000
Private Placement	$ 223		314,977		315,200
Private Placement (in Shares)	2,229,231
Treasury stock					(26,000)
Common stock issued	$ 77	$ (512,075)	511,998		0
Common stock issued (in Shares)	769,598	(769,598)
Net loss				(1,484,313)	(1,484,313)
Balance at Dec. 31, 2021	$ 3,785	$ 458,519	$ 8,183,082	$ (8,478,060)	$ 141,326
Balance (in Shares) at Dec. 31, 2021	37,849,405	4,265,295

Financial Statements

Financial Statements	12 Months Ended
	Dec. 31, 2021
Financial Statements [Abstract]
FINANCIAL STATEMENTS	NOTE 1 – FINANCIAL STATEMENTS Organization AVRA Medical Robotics, Inc. (the “Company” or “AVRA”) was incorporated as AVRA Surgical Microsystems, Inc. in the State of Florida on February 4, 2015. Effective November 5, 2015, the Company’s corporate name was changed to AVRA Medical Robotics, Inc. The Company was established to develop advanced medical surgical devices. The Company is structured to invest in four principal areas – surgical robotic systems, surgical tools, implantable devices and surgical robotic training. Basis of Presentation The accompanying financial statements are prepared on the basis of accounting principles generally accepted in the United States of America (“GAAP”). The Company is a development-stage enterprise devoting substantial efforts to establishing a new business, financial planning, raising capital, and research into products which may become part of the Company’s product portfolio. The Company has not realized sales through December 31, 2020. A development stage company is defined as one in which all efforts are devoted substantially to establishing a new business and, even if planned principal operations have commenced, revenues are insignificant. Going Concern The accompanying financial statements have been prepared assuming the continuation of the Company as a going concern. At December 31, 2021, the Company’s stockholders’ deficit was $8,400,668 which raises substantial doubt about the Company. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and is dependent on debt and equity financing to fund its operations. Management of the Company is making efforts to raise additional funding until a registration statement relating to an equity funding facility is in effect. While management of the Company believes that it will be successful in its capital formation and planned operating activities, there can be no assurance that the Company will be able to raise additional equity capital, or be successful in the development and commercialization of the products it develops or initiates collaboration agreements thereon. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses. The Company regularly evaluates estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates made by management. Cash and Cash Equivalents The Company considers all cash on hand, cash accounts not subject to withdrawal restrictions or penalties, and all highly liquid debt instruments purchased with a maturity of three months or less to be cash and cash equivalents. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. The Company maintains its principal cash balance in a financial institution. These balances are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At December 31, 2021 and 2020, $147,460 and $0, respectively, were in excess of the FDIC insured limit. Revenue Recognition In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606). The ASU and all subsequently issued clarifying ASUs replaced most existing revenue recognition guidance in U.S. GAAP. The ASU also required expanded disclosures relating to the nature amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The Company adopted the new standard effective January 1, 2018, the first day of the Company’s fiscal year. For these reasons, the adoption of this ASU did not have a significant impact on the Company’s financial statements Effective January 1, 2018, the Company adopted guidance issued by the FASB regarding recognizing revenue from contracts with customers. The revenue recognition policies as enumerated below reflect the Company's accounting policies effective January 1, 2018, which did not have a materially different financial statement result than what the results would have been under the previous accounting policies for revenue recognition. Revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements: Step 1: Identify the contract(s) with customers Step 2: Identify the performance obligations in the contract Step 3: Determine the transaction price Step 4: Allocate the transaction price to performance obligations Step 5: Recognize revenue when the entity satisfies a performance obligation As the Company had no business operations during the year ended December 31, 2021 and 2020 we have not identified specific planned revenue streams. During the year ended December 31, 2021 and 2020, we did not recognize any revenue. Equipment Equipment is recorded at cost and depreciated using the straight-line method at rates determined to estimate the useful lives of the assets. The annual rates used in calculating depreciation are as follows: Equipment -5 years straight-line The Company originally purchased medical equipment for a total cost of $75,000 which was 100% financed by the seller. After making several payments, the Company settled with the vendor due to issues with equipment, and was relieved of the $25,000 balance owed as of first quarter 2020. The total amount paid of $50,000 represents the actual cost. During the year 2021, there is no addition. Intangibles Intangible assets continue to be subject to amortization, and any impairment is determined in accordance with ASC 360, “Property, Plant, and Equipment,” intangible assets are stated at historical cost and amortized over their estimated useful lives. The Company uses a straight-line method of amortization, unless a method that better reflects the pattern in which the economic benefits of the intangible asset are consumed or otherwise used up can be reliably determined The Company purchased existing Intellectual Property from the University of Central Florida. Management regularly assesses the carrying value of the intellectual property to determine if there has been any diminution of value. Website Website is recorded at cost and it has been fully amortized during the year. The Company originally designed a website in February 2018 for a total cost of $36,000 out of which $14,400 was paid via bank transfer and the balance was paid by issuing 24,000 shares. In 2019, the company incurred a small expense of $121.93 which was paid via bank transfer. $36,000 has been amortized using the straight-line method over its estimated life of 3 years, and $121.93 is amortized in this year. Long-lived Assets In accordance with ASC 360, “ Property Plant and Equipment Stock Compensation Expense The Company accounts for equity instruments issued in exchange for the receipt of goods or services from other than employees in accordance with Accounting Standards Codification ("ASC") Topic 505, "Equity." Costs are measured at the estimated fair market value of the consideration received or the estimated fair value of the equity instruments issued, whichever is more reliably measurable. The value of equity instruments issued for consideration other than employee services is determined on the earlier of a performance commitment or completion of performance by the provider of goods or services as defined by ASC Topic 505. Income Taxes The Company accounts for income taxes pursuant to ASC Topic 740 " Income Taxes. The Company applies the provisions of ASC Topic 740-10-05 " Accounting for Uncertainty in Income Taxes Basic and Diluted Loss per Share In accordance with ASC Topic 260 " Earnings Per Share, Research and Development Costs In accordance with ASC Topic 730 "Research and Development", with the exception of intellectual property that is purchased from another enterprise and have alternative future use, research and development expenses are charged to operations as incurred. Fair Value of Financial Instruments Our financial instruments consist principally of accounts receivable, amounts due to related parties and promissory notes payable. The carrying amounts of cash and cash equivalents and promissory notes approximate fair value because of the short-term nature of these items. Recent Accounting Pronouncements Compensation- Stock Compensation In May 2017, the FASB issued ASU 2017-09, “Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting,” that provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. The new guidance became effective for the Company on January 1, 2018 and was applied on a prospective basis, as required. The adoption of this standard did not have an impact on the financial statements or the related disclosures. Leases In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). The FASB issued ASU 2016-02 to increase transparency and comparability among organizations recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Under ASU 2016-02, lessors will account for leases using an approach that is substantially equivalent to existing GAAP for sales-type leases, direct financing leases and operating leases. Unlike current guidance, however, a lease with collectability uncertainties may be classified as a sales-type lease. If collectability of lease payments, plus any amount necessary to satisfy a lessee residual value guarantee, is not probable, lease payments received will be recognized as a deposit liability and the underlying assets will not be derecognized until collectability of the remaining amounts becomes probable. ASU 2016-02 is effective for interim and annual periods beginning after December 15, 2018, with early adoption permitted, and must be adopted using a modified retrospective transition. The Company did not adopt the standard effective January 1, 2019, utilizing the lessor practical expedient. On November 15, 2019, the FASB issued ASU 2019-10 which amended the effective dates for ASC 842, to give implementation relief. Under the FASB's new framework, two "buckets" were defined, bucket 1 includes public companies that are SEC filers but excludes "Small Reporting Companies" (SRC's). Bucket 2 includes all other entities, including SRC's. Bucket 2 entities have to apply ASC 842 for fiscal years beginning after December 15, 2020, and interim periods within fiscal years beginning after December 15, 2021.

Investment

Investment	12 Months Ended
	Dec. 31, 2021
Investment [Abstract]
INVESTMENT	NOTE 3 – INVESTMENT On November 6, 2020, AVRA made an investment (the “Investment”) of $210,000 in Avra Air, LLC which was made with $40,000 in cash and the balance by the issuance to Avra Air, LLC of 472,222 restricted common shares of AVRA valued at $0.36 per Share. In exchange for the Investment AVRA received (a) a 49.8% limited liability company membership interest in Avra Air, LLC; and (b) the remaining 50% of a vehicular air sterilization provisional patent that AVRA did not yet control. In addition, AVRA agreed to pay Avra Air, LLC a royalty payment of $1.50 per vehicular air sterilization kit for two years from the date that a first kit that uses the patent is sold. On December 22, 2020, the Company issued 472,222 shares of its common stock towards its acquisition of Avra Air. LLC. Investment in Avra Air- LLC was reduced by $12,150 in the second quarter of 2021 as a result of an investor’s follow-on investment. An impairment charge of $77,392 was then taken in the last quarter of 2021. As the $26,000 remaining balance was paid for in the original investment using Avra Medical shares this remaining balance is considered a buy-back of Avra Medical common shares and are thus treated as treasury shares shown in the equity section of the balance sheet. This results in a $0 cost on the books for this investment.

Notes Payable _ Related Party

Notes Payable – Related Party	12 Months Ended
	Dec. 31, 2021
Notes Payable – Related Party [Abstract]
NOTES PAYABLE – RELATED PARTY	NOTE 4 – NOTES PAYABLE – RELATED PARTY On December 31, 2018, the Company borrowed $15,000 under a non-interest bearing promissory note from a related party. The note matured on December 31, 2019 and was extended to December 31, 2020. On February 6, 2019, the Company borrowed from its CEO, $17,500 under a non interest bearing promissory note which matures on February 6, 2020 and was extended to December 31, 2020. On June 26, 2019, the Company borrowed from its CEO, $40,000 under a non interest bearing promissory note which matures on June 26, 2020 and was extended to December 31, 2020. On October 11, 2019, the Company borrowed from its CEO, $30,000 under a non interest bearing promissory note which matures on March 11, 2020 and was extended to December 31, 2020. On November 14, 2019, the Company borrowed from its CEO, $7,000 under a non interest bearing promissory note which matures on November 14, 2020 and was extended to December 31, 2020. On December 3, 2019, the Company borrowed from its CEO, $3,000 under a non interest bearing promissory note which matures on December 3, 2020. On December 6, 2019, the Company borrowed from its CEO, $30,000 under a non interest bearing promissory note which matures on December 6, 2020. On December 30, 2019, the Company borrowed from its CEO, $25,000 under a non interest bearing promissory note which matures on December 30, 2020. On March 31, 2020, the Company borrowed from its CEO, $6,000 under a non interest bearing promissory note which matures on December 31, 2020. On August 21, 2020, the Company borrowed from its CEO, $17,700 under a non interest bearing promissory note which matures on December 31, 2020 (see below). On October 19, 2020, the Company borrowed from its CEO, $11,500 under a non interest bearing promissory note which matures on December 31, 2021. On December 22, 2020, these notes totaling $202,700, totaling 202,700 units were all converted into 810,800 shares of common shares and a warrant was issued for 1,013,500 shares with an exercise price of $0.40/share. On May 4, 2020, the Company borrowed from its CEO, $2,500. On June 1, 2020, the Company borrowed from its CEO, $4,000. On June 30, 2020, the Company borrowed from its CEO, $5,000. On July 15, 2020, the Company borrowed from its CEO, $2,000. On July 20, 2020, the Company borrowed from its CEO, $1,000. On August 7, 2020, the Company borrowed from its CEO, $1,200. On August 21, 2020, the Company borrowed from its CEO, $2,000. On August 21, 2020, the Company entered into a non interest bearing promissory note with the total above combined funds of $17,700 which matures on December 31, 2020. This note was then part of the December 22, 2020 conversion (see above). On May 8, 2019, the Company borrowed from its CEO, $25,000 under a non interest bearing promissory note which matures on May 8, 2020 and was extended to December 31, 2020 then subsequently extended to December 31, 2021, and on September 22, 2021 the note was converted into 384,615 shares of common stock. On May 29, 2019, the Company borrowed from its CEO, $25,000 under a non interest bearing promissory note which matures on May 29, 2020 and was extended to December 31, 2020 then subsequently extended to December 31, 2021, and on September 22, 2021 the note was converted into 384,615 shares of common stock... On July 19, 2019, the Company borrowed from its CEO, $50,000 under a non interest bearing promissory note which matures on July 19, 2020 and was extended to December 31, 2020 then subsequently extended to December 31, 2021 and then was further extended to December 31, 2022. On January 3, 2020, the Company borrowed from its CEO, $95,000 under a non interest bearing promissory note which matures on January 3, 2021. On December 22, 2020, these notes’ maturity date was extended to December 31, 2021, then was subsequently extended to December 31, 2022. As an incentive for extending theses notes the Company issued an option for 390,000 common shares with an exercise price of $0.25/share. On August 26, 2019, the Company borrowed from its CEO, $100,000 under a non interest bearing promissory note which matured on December 26, 2019. On January 5, 2020, the related party used his $100,000 note to exercise his 1,000,000 options to purchase 1,000,000 shares of the Company’s common stock at $0.10 per share. During the year ended December 31, 2020 the Company received a Payroll Protection Loan (PPP Loan) in the amount of $4,630. Prior to December 31, 2020 the Company received forgiveness on the loan. On September 22, 2021, the Company’s CEO, converted a total of $50,000 of notes payable into 384,615 shares of common stock and converted $50,000 of accrued salary into 384,615 shares of common stock.

Promissory Notes

Promissory Notes	12 Months Ended
	Dec. 31, 2021
Promissory Notes [Abstract]
PROMISSORY NOTES	NOTE 5 – PROMISSORY NOTES On December 31, 2018, the Company borrowed $15,000, with interest payable annually at 4%, maturing on December 31, 2019. This note was paid in full on January 7, 2020. During January 2019, the Company borrowed $20,000 under a non interest bearing promissory note which matures on December 31, 2019, this amount was converted to 13,334 shares of common stock in 2020. On March 11, 2019, the Company borrowed $25,000 under a promissory note bearing an annual interest rate of 5% and which matures on September 11, 2019. The loan includes a warrant to purchase 12,500 common shares at a strike price of $1.25 per share. The warrant expires in 3 years. This note was paid in full on January 16, 2020. On March 14, 2019, the Company borrowed $25,000 under a promissory note bearing an annual interest rate of 5% and which matures on September 14, 2019 and was extended until December 31, 2020. The loan includes a warrant to purchase 12,500 common shares at a strike price of $1.25 per share. The warrant expires in 3 years. This note was paid in full on October 31, 2020. On March 29, 2019, the Company borrowed $25,000 under a promissory note bearing an annual interest rate of 5% and which matures on September 29, 2019. The loan includes a warrant to purchase 12,500 common shares at a strike price of $1.25 per share. The warrant expires in 3 years. This note was paid in full on January 21, 2020. During the years ended 2020 and 2021, 2,643,635 and 1,175,000 warrants, were valued at $471,825 and $912,489 using a black-scholes pricing model and expensed as stock compensation, respectively.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Taxes [Abstract]
INCOME TAXES	NOTE 6 – INCOME TAXES The Company’s deferred tax assets at December 31, 2021 consist of net operating loss carry forwards of $4,393,785. Using a new federal statutory tax rate of 21%, the valuation allowance balance as of December 31, 2020 total of $0. The increase in the valuation allowance balance for the year ended December 31, 2021 of $221,827 is entirely attributable to the net operating loss. Due to the uncertainty of their realization, no income tax benefits have been recorded by the Company for these loss carry forwards as valuation allowances have been established for any such benefits. The increase in the valuation allowance was the result of increases in the net operating losses discussed above. Therefore, the Company’s provision for income taxes is $-0- for the years ended December 31, 2021 and 2020. At December 31, 2021 and 2020, the Company had no material unrecognized tax benefits and no adjustments to liabilities or operations were required. The Company does not expect that its unrecognized tax benefits will materially increase within the next twelve months. The Company recognizes interest and penalties related to uncertain tax positions in general and administrative expense. At December 31, 2021 and 2020, the Company has not recorded any provisions for accrued interest and penalties related to uncertain tax positions. The Company files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations.

Stockholders' Deficit

Stockholders' Deficit	12 Months Ended
	Dec. 31, 2021
Stockholders' Deficit [Abstract]
STOCKHOLDERS’ DEFICIT	NOTE 7 – STOCKHOLDERS’ DEFICIT The Company is authorized to issue up to 100,000,000 shares of common stock, $0.0001 par value per share plus 5,000,000 shares of preferred stock, par value $0.0001. On February 23, 2018, the board of directors of AVRA authorized the issuance of an aggregate of 218,000 shares of AVRA’s common stock (the “Shares”) as follows: ● 150,000 Shares at a value of $1.25 per Share, to six consultants and service providers for services rendered through December 31, 2017; ● 35,000 Shares, at a value of $1.25 per Share, to Farhan Taghizadeh, M.D., AVRA’s Chief Medical Officer, for services rendered during the period September 1, 2017 to December 31, 2017; and ● 19,500 and 13,500 Shares, at a value of $2.00 per Share, to Barry F. Cohen and A. Christian Schauer, our Chief Executive Officer and its former Chief Financial Officer, respectively, pursuant to Conversion Agreements with each of such officers, under which they converted all December 31, 2017 accrued but unpaid compensation due them under their respective employment agreements with the Company into the Shares. On August 13, 2018 the Company sold 16,000 shares of its common stock for $20,000. On October 4, 2018, the Board of Directors adopted the following resolutions and took the following actions by unanimous written consent in lieu of a meeting in accordance with the applicable provisions of the Florida business Corporation Act: ● 128,300 shares of restricted common stock required to be issued, to six consultants and service providers for services rendered through September 30, 2018; ● 400 shares of restricted common stock required to be issued, for services rendered through February 28, 2018; On January 4, 2019, 115,050 shares at a value of $1.25 per share were issued for service rendered. On April 1, 2019, 95,050 shares at a value ranging from $1.25-$2.41 per share were issued for services rendered. On July 1, 2019, 79,672 shares at a value ranging from $1.25-$2.76 per share were issued for services rendered. On August 28, 2019, 600,000 shares at a value ranging from $1.25-$2.00 per share were issued for services rendered. On December 1, 2019, the Company canceled 250,000 restricted shares of the Company’s common stock that were previously issued to its CEO under a Stock Award letter dated August 28, 2019. On November 6, 2020, AVRA issued an aggregate 256,027 Units (“Units”) at a price of $1.00 per Unit in a private offering (the “Offering”) to four “accredited investors.” Each Unit consisted of (a) four shares of our common stock (“Shares”); (b) a three-year warrant to purchase five Shares at an exercise price of $0.40 per Share; and (c) a 0.00008749_% limited liability company membership interest in Avra Air, LLC (“Avra Air”), a development stage company, which interest may be put to the Company at the option of the investor for a period of two years from issuance, in exchange for one Share. As a result of the foregoing, the investors were issued an aggregate of 1,024,108 Shares, warrants to purchase 1,280,135 Shares and a 22.4% limited liability company membership interest in Avra Air, LLC. On October 26, 2020, the Company received a commitment to sell 135,000 units for $135,000. A $25,000 promissory note plus accrued interest of $1,027 was converted towards the commitment for 26,027 units (this amount is included above). On November 6, 2020, AVRA issued an aggregate of 321,489 Shares as follows: ● 10,000 Shares to its Director Arthur Tomassetti per his prior advisory agreement; and ● 220,489 Shares to seven consultants, advisors, and service providers for services rendered through November 1, 2020; and ● 70,000 Shares to Farhan Taghizadeh, M.D., AVRA’s Chief Medical Officer, for services thru November 1, 2020; and ● 21,000 Shares for a stock option exercised by an investor at an exercise price of $0.10 per Share. During 2020, the Company’s CEO converted $302,700 of its notes payable into 1,810,800 shares of common stock. On December 22, 2020, the Company issued 472,222 shares of its common stock towards its acquisition of Avra Air (See Note 3). During the first quarter 2021, 1,025,00 During the second quarter 2021, 378,378 shares at a value ranging from $0.89-$1.02 per share were issued for services rendered. In July, 2021 several holders of stock options elected to exercise their stock options with a cashless exercise provision resulting in the issuance of 629,375 shares of common stock. During the last quarter 2021, 3,619,817 shares at a value ranging from $0.13-$0.89 per share were issued for services rendered. On October 1, 2021 the Company issued a total of 174,553 shares of common stock to several consultants. On October 1, 2021 the Company issued 25,000 shares of common stock to its Chief Medical Officer. Holders are entitled to one vote for each share of common stock. No preferred stock has been issued.

2016 Incentive Stock Plan

2016 Incentive Stock Plan	12 Months Ended
	Dec. 31, 2021
2016 Incentive Stock Plan [Abstract]
2016 INCENTIVE STOCK PLAN	NOTE 8 – 2016 INCENTIVE STOCK PLAN On August 1, 2016, the Company adopted the 2016 Incentive Stock Plan (the “Plan”). The Plan provides for the granting of options to employees, directors, consultants and advisors to purchase up to 3,000,000 shares of the Company’s common stock. The Board is responsible for administration of the Plan. The Board determines the term of each option, the option exercise price, the number of shares for which each option is granted and the rate at which each option is exercisable. Incentive stock options may be granted to any officer or employee at an exercise price per share of not less than the fair market value per common share on the date of the grant. On August 1, 2019, the Board increased the plan to 10,000,000 shares of common stock. For options granted October 1, 2017, the following factors were used: volatility 45.07%; expected term of 3 years, risk-free interest rate of 2.00%, dividend yield of 0% and exercise price of $1.25 per share. For options granted July 1, 2018, the following factors were used: volatility 31.34%; expected term of 3 years, risk-free interest rate of 2.00%, dividend yield of 0% and exercise price of $1.25 per share. For options granted May 1, 2018, the following factors were used: volatility 62.16%; expected term of 3 years, risk-free interest rate of 2.00%, dividend yield of 0% and exercise price of $1.25 per share. On July 1, 2018 options for 75,000 shares were issued to our Counsel for services rendered totaling $21,000. These shares are vested immediately and expire on July 1, 2023. The exercise price is $1.25. For the year ended December 31, 2019 and 2018, 210,000 and -0- options were exercised, respectively. Non-vested Options for 97,639 shares were forfeited during March 2018. On December 1, 2019, the Company granted to its majority shareholder options to purchase 750,000 common shares of the Company at an exercise price per share will be $1.00. All shares will immediately vest, and the Option will expire five years from the date of issuance. At December 31, 2020 and 2019 options representing 4,327,167 shares and 3,276,667 shares were vested or exercisable, respectively. All options issued to-date expire after five years from the issue date. Except for the option for 1,779,000 shares issued to the CEO and to the Company’s counsel for 40,000 shares that vested immediately, all the options issued to date vest over three years. Stock options are accounted for in accordance with FASB ASC Topic 718, Compensation –Stock Compensation The grant date fair value of options granted during the year of 2018 were estimated on the grant date using the Black-Scholes model with the following assumptions: For options granted May 1, 2018, the following factors were used; volatility 62.16%; expected term of 3 years, risk-free interest rate of 2.00%, dividend yield of 0% and exercise price of $1.25 per share. For options granted July 1, 2018, the following factors were used; volatility 31.34%; expected term of 3 years, risk-free interest rate of 2.00%, dividend yield of 0% and exercise price of $1.25 per share. The grant date fair value of options granted during the year of 2019 were estimated on the grant date using the Black-Scholes model with the following assumptions: For options granted February 1, 2019: Volatility 50.58%, term 3yrs, risk-free interest rate of 2.00%, dividend yield of 0% and exercise price of $2.00 per share. For options granted April 1, 2019: Volatility 48.52%, term 3yrs, risk-free interest rate of 2.00%, dividend yield of 0% and exercise price of $1.25 per share. For options granted August 1, 2019: Volatility 62.43%, term 3yrs, risk-free interest rate of 2.00%, dividend yield of 0% and exercise price of $2.00 per share. For options granted October 1, 2019: Volatility 48.57%, term 3yrs, risk-free interest rate of 2.00%, dividend yield of 0% and exercise price of $2.00 per share. For options granted December 1, 2019: Volatility 61.91%, term 3yrs, risk-free interest rate of 2.00%, dividend yield of 0% and exercise price of $1.00 per share. For the warrants granted on October 26, 2020 the fair market value used was $0.40, exercise $0.40, rate 2%, and volatility 44.35%. The warrants granted on December 22, 2020: Fair market value used was $0.468, exercise $0.40, rate 2%, and volatility 71.79%. For the options granted on December 22 2020 the fair market value used was $0.468, exercise $0.25, rate 2%, and volatility 71.79%. For the warrants granted on January 26 2021 the fair market value used was $0.980, exercise $0.40, rate 2%, and volatility 106.16%. On October 1, 2021 the Company issued a total of 1,500,000 of stock options to consultants with an exercise price of $0.25 per option. On October 1, 2021 the Company issued 50,000 stock options to each of its two independent Directors with an exercise price of $0.25 per option. On October 1, 2021 the Company issued 350,000 stock options to its Chief Medical Officer with an exercise price of $0.25 per option. On October 1, 2021 the Company issued a total of 390,000 stock options to the Company’s CEO with an exercise price of $0.25 per option for the extension of loans. Expected volatilities are based on the average volatilities of six similar companies; fair market values are calculated using the implied share values of recent company financings or OTC closing prices for that day, whichever is more suitable; risk-free rate used was 2%.

Commitments

Commitments	12 Months Ended
	Dec. 31, 2021
Commitments [Abstract]
COMMITMENTS	NOTE 9 – COMMITMENTS Intellectual property The Company purchased existing Intellectual Property from the University of Central Florida. Management regularly assesses the carrying value of the intellectual property to determine if there has been any diminution of value. Effective May 1, 2016, the Company entered into a Research Agreement (the “Research Agreement”) with the University of Central Florida (“UCF” or the “University”) for the development of a prototype surgical robotic device supporting minimal invasive surgical facial corrections. The Agreement provides that the University will provide personnel to accomplish the objectives as stated in the Statement of Work over a period extending to September 30, 2017. Effective May 1, 2016, the research agreement with the University of Central Florida has been extended to April 30, 2021. The Company agreed to extend funding of $163,307 from AVRA’s existing funds. The Company paid $43,548 for outright ownership of the University’s Intellectual Property resulting from the collaboration, which amount is shown as Intellectual Property. Management has assessed the carrying value of the asset at December 31, 2019 and has recorded an impairment loss in the amount of $43,548 for the year ended December 31, 2019. For the years ended, December 31, 2021 and 2020, $-0- had been paid under the Agreement. The balance of the amount owing to the University was fully paid on February 24, 2017 and April 7, 2017. Additionally, a $68,952 matching funds grant from the Florida High Tech Corridor Council (FHTCC) was approved on July 16, 2016 which would provide the University research funds in addition to the Company’s funding obligation to the University. The FHTCC research grant is subject to certain research obligations and action requirements which if not met may result in the loss of the FHTCC research funding. The agreement further provides for the payment of a 1% royalty to the University in any year when the sales of products using the intellectual property exceeds $20,000,000. Employment Agreements On July 1, 2016, the Company entered into an Employment Agreement with its Chairman and Chief Executive Officer. The agreement provides for an annual salary of $120,000 per year, increasing to $180,000 per year beginning July 2017. Through December 2016, the employee agreed to not receive the compensation in cash until the Board of Directors deemed it prudent to pay some or all of his salary. Further the Agreement provides that the employee will receive a three-year option to purchase 1,000,000 shares of the Company’s common stock at an exercise price of $0.10 per share, and becoming fully vested on August 15, 2016. On August 1, 2016, the Company entered into a one-year Employment Agreement with its Chief Financial Officer. The agreement provides for an annual salary of $108,000 per year. Through December 2016, the employee agreed to not receive the compensation in cash until the Board of Directors deemed it prudent to pay some or all of his salary. Further the Agreement provides that the employee will receive a three-year option to purchase 210,000 shares of the Company’s common stock at an exercise price of $0.10 per share, with 70,000 shares becoming fully vested upon each yearly anniversary. The options are to be surrendered and cancelled if the Agreement is terminated. The Agreement has expired but its compensation terms continue in effect as long as the employee remains employed by the Company. On August 1, 2016, the Company entered into a three-year Employment Agreement with its Vice President of Global Business Development. The agreement provides for an annual salary of $96,000 per year, increasing to $144,000 per year beginning July 2017. Through December 2016, the employee agreed to not receive the compensation in cash until the Board of Directors deemed it prudent to pay some or all of his salary. Further the Agreement provides that the employee will receive a three-year option to purchase 300,000 shares of the Company’s common stock at an exercise price of $0.10 per share, with 100,000 shares vested on each yearly anniversary. Further, on July 1, 2016, the Company entered into Indemnification Agreements with the Chairman and Chief Executive Officer, and on August 1, 2016 the Chief Financial Officer and the Vice-President of Global Business Development providing for the Company to indemnify the individuals for all expenses, judgments, etc. incurred while serving in various capacities with the Company. Commencing March 1, 2018, the Company entered into an employment agreement with its new Chief Strategy Officer whereby compensation will be determined upon sufficient funding of the Company. The Company granted a 300,000 share stock award under its 2016 Incentive Stock Plan, which vests in five equal annual installments of 60,000 shares each. In addition, on May 1, 2018 options for 250,000 shares that vest monthly over 3 years were also issued to our Chief Strategy Officer. These options expire on May 1, 2023 and are exercisable at $1.25. Commencing January 1, 2019, the Company entered into a consulting agreement with an IR/PR Company whereby compensation will be $1,500 per month for six months. During third quarter 2019, these services stopped. On July 1, 2019, the Company issued 36,000 restricted common shares as part of the compensation. Effective July, 1, 2020, the Company entered into an employee agreement with its Chairman and Chief Executive Officer, for a term of 48 months. The employee’s base salary is $15,000 monthly, beginning with the July 2020 payment, which rate shall be inclusive of all claims by the employee for his services. However, employee agrees to accrue his salary from the July 1, 2020 through and including December 2020 and allows the Board of Directors to decide on whether to convert any or all accrued salary into Company restricted common shares. Beginning on the July 1, 2020, normal direct business expenses will be covered, including business class travel on flights over 5 hours. Employee will receive a $500 per month vehicle expense stipend to help mitigate the costs of the frequent travel required to visit the Orlando office and University of Central Florida from the employee’s home. Employee will also be granted an option pursuant to the Company’s Equity Incentive Plan to purchase 1,000,000 restricted shares of the Company’s common stock, with an exercise price of $0.25 per share, and a Start Date of July 1, 2020. All 1,000,000 shares were fully vested on July 1, 2020. Lease The Company occupies office and laboratory space in Orlando, Florida under a lease agreement that expired on July 31, 2018. Effective August 1, 2018 and expiring July 31, 2019, the Company signed a new agreement, with monthly payments of $1,829.25 plus applicable sales tax. Effective August 1, 2019, the Company signed a year lease agreement, provides that the Company pay insurance, maintenance and taxes with a monthly lease expense of $2,454.75 plus applicable sales tax. Effective January 15, 2020, the Company amended its August 1, 2019 lease agreement reducing its monthly lease payment to $2,223 plus applicable sales tax. On April 30, 2020, the rent due under our lease agreement had been reduced by 50% for the months of April and May, 2020. On July 17, 2020, the Company signed a lease that was effective August 1, 2020 through July 31, 2021, which provides that the Company pay insurance, maintenance and taxes with a monthly lease expense of $1,474.17 plus applicable sales tax. Effective January 1, 2021, the Company signed an amendment which modified the August 1, 2020 agreement, increasing the monthly lease expense to $1,964.74 plus applicable sales tax. Either party may cancel the agreement at any time with 30 days’ notice.

Other Matters

Other Matters	12 Months Ended
	Dec. 31, 2021
Other Matters [Abstract]
OTHER MATTERS	NOTE 10 – OTHER MATTERS On January 30, 2020, the World Health Organization (“WHO”) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the “COVID-19 outbreak”) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. The full impact of the COVID-19 outbreak continues to evolve as of the date of this report. As such, it is uncertain as to the full magnitude that the pandemic will have on the Company’s financial condition, liquidity, and future results of operations. Management is actively monitoring the global situation on its financial condition, liquidity, operations, suppliers, industry, and workforce. Given the daily evolution of the COVID-19 outbreak and the global responses to curb its spread, the Company is not able to estimate the effects of the COVID-19 outbreak on its results of operations, financial condition, or liquidity for fiscal year 2020. On March 27, 2020, President Trump signed into law the “Coronavirus Aid, Relief, and Economic Security (CARES) Act.” The CARES act was enacted as a response to the COVID-19 outbreak discussed above and is meant to provide companies with economic relief. The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carry back periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, increased limitations on qualified charitable contributions, and technical corrections to tax depreciation methods for qualified improvement property.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 11 – SUBSEQUENT EVENTS The Company has evaluated subsequent events through the date that the financial statements were issued and determined that there were subsequent events requiring adjustments to or disclosure in the financial statements. On July 1, 2022 the Company paid $5,000 and issued to a consultant an option for 2,520,000 common shares with an exercise price of $0.10 per share as a performance bonus and for foregoing all accrued and unpaid fees due for 2022 and for foregoing a portion of the fees due for the remaining five months of calendar year 2022. The option vested immediately. On July 1, 2022 the Company issued to its CEO an option for 5,400,000 common shares with an exercise price of $0.10 per share as a performance bonus and for foregoing all of his 2022 salary. The option vested immediately. On July 1, 2022 the Company issued to its Chief Medical Officer an option for 500,000 common shares with an exercise price of $0.10 per share as a performance bonus. The option vested immediately. On July 1, 2022 the Company issued to its Chief Strategy Advisor an option for 500,000 common shares with an exercise price of $0.10 per share as a performance bonus. The option vested immediately. On July 1, 2022 the Company issued 240,270 shares of common stock as payment in full for the accrued but unpaid fees due to its Counsel. On July 1, 2022 the Company issued 27,250 shares of common stock to its patent attorney per their fee agreement. On July 1, 2022 the Company issued 160,000 shares of common stock to its Chief Strategy Officer as required by his Stock Grant Award dated April 15, 2019 and his Employment Agreement dated March 1, 2018. On July 1, 2022 the Company issued 40,000 shares of common stock to its Chief Medical Officer as required by his employment agreement dated September 15, 2020 On July 1, 2022 the Company issued a total of 569,747 shares of common stock to several consultants. In July 2022, four investors exercised their put options obtained from the Offering dated October 26, 2020, transferred their Membership Units in Avra Air LLC back to AVRA and received 301,027 shares of the Company’s common stock in return. On July 25, 2022 the Directors and Shareholders holding a majority of the issued and outstanding common shares of the Company adopted, by joint written consent, a resolution to increase the Company's common stock reserved for issuance under the Company’s 2016 Incentive Stock Plan to 20,000,000. On August 5, 2022, AVRA entered into a non-binding letter of intent with Dr. Sudhir Srivastava (“ Dr. Srivastava Cardio Otto SSI SSI Parties Transaction SSI Intellectual Property If and when the transaction is consummated, the business of the SSI Parties, including the SSI Intellectual Property will be owned by AVRA. The shareholders of the SSI Parties will own 95% of the common stock of post-transaction AVRA and the current shareholders of AVRA will own 5% of the common stock of post-transaction AVRA. In addition, there will be changes in composition of the board of directors, implementation of corporate governance policies and changes in management, all with a view to listing the common stock of AVRA on the Nasdaq Stock Market, LLC or another National Securities Exchange. In addition, AVRA will change its name to “ SS Innovations, Inc. Consummation of the Transaction is subject to, among other matters, the negotiation and execution of definitive agreements and documentation, containing, in addition to the above terms, terms and conditions customary for agreements of this type and nature, including, without limitation, representations, warranties, and indemnities of the parties. Consummation of the Transaction is also subject to completion of a due diligence review by each party of the other, the results of which shall be satisfactory to the reviewing parties in their sole discretion. Given the foregoing, there can be no assurance given that the Company will be able to successfully complete the Transaction. In connection with executing the letter of intent, we advanced the SSI Parties, the amount of $990,000 (the “ Interim Financing Cardio Notes We may make additional advances to the SSI Parties of up to an aggregate principal amount of $5,000,000 of Interim Financing, evidenced by additional Cardio Notes. These Cardio Notes will be substantially similar in form and substance to the first Cardio Notes, provided however 2.000,000 In order to fund the Interim Financing, the Company offered and sold to two accredited investors, $1,000,000 and $100,000 one-year convertible promissory notes (the “ Convertible Notes provided however The Convertible Notes were issued in a private transaction pursuant to the exemptions from registration under the Section 4(a)2 of the Securities Act of 1933, as amended (the “ Securities Act In August 2022 the Company sold 1,000,000 shares of common stock at a price of $0.25 per share receiving proceeds of $250,000. On September 7 th In September 2022 and thru the date of this document, the Company sold 1,631,000 shares of common stock at a price of $0.25 per share receiving proceeds of $407,750.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Estimates	Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses. The Company regularly evaluates estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates made by management.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all cash on hand, cash accounts not subject to withdrawal restrictions or penalties, and all highly liquid debt instruments purchased with a maturity of three months or less to be cash and cash equivalents.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. The Company maintains its principal cash balance in a financial institution. These balances are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At December 31, 2021 and 2020, $147,460 and $0, respectively, were in excess of the FDIC insured limit.
Revenue Recognition	Revenue Recognition In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606). The ASU and all subsequently issued clarifying ASUs replaced most existing revenue recognition guidance in U.S. GAAP. The ASU also required expanded disclosures relating to the nature amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The Company adopted the new standard effective January 1, 2018, the first day of the Company’s fiscal year. For these reasons, the adoption of this ASU did not have a significant impact on the Company’s financial statements Effective January 1, 2018, the Company adopted guidance issued by the FASB regarding recognizing revenue from contracts with customers. The revenue recognition policies as enumerated below reflect the Company's accounting policies effective January 1, 2018, which did not have a materially different financial statement result than what the results would have been under the previous accounting policies for revenue recognition. Revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements: Step 1: Identify the contract(s) with customers Step 2: Identify the performance obligations in the contract Step 3: Determine the transaction price Step 4: Allocate the transaction price to performance obligations Step 5: Recognize revenue when the entity satisfies a performance obligation As the Company had no business operations during the year ended December 31, 2021 and 2020 we have not identified specific planned revenue streams. During the year ended December 31, 2021 and 2020, we did not recognize any revenue.
Equipment	Equipment Equipment is recorded at cost and depreciated using the straight-line method at rates determined to estimate the useful lives of the assets. The annual rates used in calculating depreciation are as follows: Equipment -5 years straight-line The Company originally purchased medical equipment for a total cost of $75,000 which was 100% financed by the seller. After making several payments, the Company settled with the vendor due to issues with equipment, and was relieved of the $25,000 balance owed as of first quarter 2020. The total amount paid of $50,000 represents the actual cost. During the year 2021, there is no addition.
Intangibles	Intangibles Intangible assets continue to be subject to amortization, and any impairment is determined in accordance with ASC 360, “Property, Plant, and Equipment,” intangible assets are stated at historical cost and amortized over their estimated useful lives. The Company uses a straight-line method of amortization, unless a method that better reflects the pattern in which the economic benefits of the intangible asset are consumed or otherwise used up can be reliably determined The Company purchased existing Intellectual Property from the University of Central Florida. Management regularly assesses the carrying value of the intellectual property to determine if there has been any diminution of value.
Website	Website Website is recorded at cost and it has been fully amortized during the year. The Company originally designed a website in February 2018 for a total cost of $36,000 out of which $14,400 was paid via bank transfer and the balance was paid by issuing 24,000 shares. In 2019, the company incurred a small expense of $121.93 which was paid via bank transfer. $36,000 has been amortized using the straight-line method over its estimated life of 3 years, and $121.93 is amortized in this year.
Long-lived Assets	Long-lived Assets In accordance with ASC 360, “ Property Plant and Equipment
Stock Compensation Expense	Stock Compensation Expense The Company accounts for equity instruments issued in exchange for the receipt of goods or services from other than employees in accordance with Accounting Standards Codification ("ASC") Topic 505, "Equity." Costs are measured at the estimated fair market value of the consideration received or the estimated fair value of the equity instruments issued, whichever is more reliably measurable. The value of equity instruments issued for consideration other than employee services is determined on the earlier of a performance commitment or completion of performance by the provider of goods or services as defined by ASC Topic 505.
Income Taxes	Income Taxes The Company accounts for income taxes pursuant to ASC Topic 740 " Income Taxes. The Company applies the provisions of ASC Topic 740-10-05 " Accounting for Uncertainty in Income Taxes
Basic and Diluted Loss per Share	Basic and Diluted Loss per Share In accordance with ASC Topic 260 " Earnings Per Share,
Research and Development Costs	Research and Development Costs In accordance with ASC Topic 730 "Research and Development", with the exception of intellectual property that is purchased from another enterprise and have alternative future use, research and development expenses are charged to operations as incurred.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Our financial instruments consist principally of accounts receivable, amounts due to related parties and promissory notes payable. The carrying amounts of cash and cash equivalents and promissory notes approximate fair value because of the short-term nature of these items.
Recent Accounting Pronouncements	Recent Accounting Pronouncements
Compensation- Stock Compensation	Compensation- Stock Compensation In May 2017, the FASB issued ASU 2017-09, “Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting,” that provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. The new guidance became effective for the Company on January 1, 2018 and was applied on a prospective basis, as required. The adoption of this standard did not have an impact on the financial statements or the related disclosures.
Leases	Leases In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). The FASB issued ASU 2016-02 to increase transparency and comparability among organizations recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Under ASU 2016-02, lessors will account for leases using an approach that is substantially equivalent to existing GAAP for sales-type leases, direct financing leases and operating leases. Unlike current guidance, however, a lease with collectability uncertainties may be classified as a sales-type lease. If collectability of lease payments, plus any amount necessary to satisfy a lessee residual value guarantee, is not probable, lease payments received will be recognized as a deposit liability and the underlying assets will not be derecognized until collectability of the remaining amounts becomes probable. ASU 2016-02 is effective for interim and annual periods beginning after December 15, 2018, with early adoption permitted, and must be adopted using a modified retrospective transition. The Company did not adopt the standard effective January 1, 2019, utilizing the lessor practical expedient. On November 15, 2019, the FASB issued ASU 2019-10 which amended the effective dates for ASC 842, to give implementation relief. Under the FASB's new framework, two "buckets" were defined, bucket 1 includes public companies that are SEC filers but excludes "Small Reporting Companies" (SRC's). Bucket 2 includes all other entities, including SRC's. Bucket 2 entities have to apply ASC 842 for fiscal years beginning after December 15, 2020, and interim periods within fiscal years beginning after December 15, 2021.

Financial Statements (Details)

Financial Statements (Details)	12 Months Ended
	Dec. 31, 2021 USD ($)
Financial Statements [Abstract]
Stockholders’ deficit	$ 8,400,668

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Details) - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended
	Feb. 28, 2018	Mar. 31, 2020	Dec. 31, 2021	Dec. 31, 2019	Dec. 31, 2020
Accounting Policies [Abstract]
FDIC insured			$ 250,000
FDIC insured limit			$ 147,460		$ 0
Equipment useful life			5 years
Purchased medical equipment			$ 75,000
Percentage financed by the seller			100%
Equipment relieved amount		$ 25,000
Total amount paid			$ 50,000
Total cost of website	$ 36,000
Bank transfer	$ 14,400			$ 121.93
Shares issued (in Shares)	24,000
Amortized of straight ine method				$ 36,000
Estimated life				3 years
Amount of amortized				$ 121.93

Investment (Details)

Investment (Details) - USD ($)		3 Months Ended	12 Months Ended
	Nov. 06, 2020	Dec. 31, 2021	Dec. 31, 2021	Jun. 30, 2021	Dec. 22, 2020
Investment (Details) [Line Items]
Price per share (in Dollars per share)	$ 1.5
Avra Air, LLC [Member]
Investment (Details) [Line Items]
Investment	$ 210,000			$ 12,150
Cash	$ 40,000
Restricted common shares (in Shares)	472,222
Price per share (in Dollars per share)	$ 0.36
Limited liability interest percentage	49.80%
Remaining percentage	50%
Shares issued (in Shares)					472,222
Impairment charges		$ 77,392
Remaining balance amount		$ 26,000	$ 26,000
Cost			$ 0

Notes Payable _ Related Party (

Notes Payable – Related Party (Details) - USD ($)

1 Months Ended

Jan. 05, 2020

Jan. 03, 2020

Dec. 06, 2019

Dec. 03, 2019

Nov. 14, 2019

Oct. 11, 2019

May 08, 2019

Feb. 06, 2019

Sep. 22, 2021

Dec. 22, 2020

Oct. 19, 2020

Aug. 21, 2020

Mar. 31, 2020

Dec. 30, 2019

Aug. 26, 2019

Jul. 19, 2019

Jun. 26, 2019

May 29, 2019

Dec. 31, 2018

Dec. 31, 2020

Aug. 07, 2020

Jul. 20, 2020

Jul. 15, 2020

Jun. 30, 2020

Jun. 01, 2020

May 04, 2020

Notes Payable – Related Party (Details) [Line Items]

Notes totaling

$ 202,700

Totaling units (in Shares)

202,700

Converted shares of common stock (in Shares)

384,615

810,800

Warrant issued shares (in Shares)

1,013,500

Exercise price per share (in Dollars per share)

$ 0.4

Related party

$ 100,000

Exercise options (in Dollars per share)

$ 1,000,000

Purchase shares (in Shares)

1,000,000

Common stock per share (in Dollars per share)

$ 0.1

Payroll protection loan amount

$ 4,630

Chief Executive Officer [Member]

Notes Payable – Related Party (Details) [Line Items]

Non-interest bearing promissory note

$ 2,000

$ 1,200

$ 1,000

$ 2,000

$ 5,000

$ 4,000

$ 2,500

Maturity date

Dec. 31, 2020

Converted shares of common stock (in Shares)

384,615

Exercise price per share (in Dollars per share)

$ 0.25

Notes Payable, Related Parties

$ 17,700

Issued an option for common shares (in Shares)

390,000

Total notes payable

$ 50,000

Accrued salary

$ 50,000

Shares of common stock (in Shares)

384,615

Promissory Note [Member]

Notes Payable – Related Party (Details) [Line Items]

Non-interest bearing promissory note

$ 15,000

Description of maturity date

The note matured on December 31, 2019 and was extended to December 31, 2020.

Promissory Note [Member] | Chief Executive Officer [Member]

Notes Payable – Related Party (Details) [Line Items]

Non-interest bearing promissory note

$ 95,000

$ 30,000

$ 3,000

$ 7,000

$ 30,000

$ 25,000

$ 17,500

$ 11,500

$ 17,700

$ 6,000

$ 25,000

$ 100,000

$ 50,000

$ 40,000

$ 25,000

Description of maturity date

matures on November 14, 2020 and was extended to December 31, 2020.

matures on March 11, 2020 and was extended to December 31, 2020.

on May 8, 2020 and was extended to December 31, 2020 then subsequently extended to December 31, 2021

matures on February 6, 2020 and was extended to December 31, 2020.

maturity date was extended to December 31, 2021, then was subsequently extended to December 31, 2022.

on July 19, 2020 and was extended to December 31, 2020 then subsequently extended to December 31, 2021 and then was further extended to December 31, 2022.

matures on June 26, 2020 and was extended to December 31, 2020.

on May 29, 2020 and was extended to December 31, 2020 then subsequently extended to December 31, 2021

Maturity date

Jan. 03, 2021

Dec. 06, 2020

Dec. 03, 2020

Dec. 31, 2021

Dec. 31, 2020

Dec. 31, 2020

Dec. 30, 2020

Dec. 26, 2019

Converted shares of common stock (in Shares)

384,615

Promissory Notes (Details)

Promissory Notes (Details) - USD ($)			1 Months Ended		12 Months Ended
	Mar. 14, 2019	Mar. 11, 2019	Mar. 29, 2019	Jan. 31, 2019	Dec. 31, 2020	Dec. 31, 2018	Dec. 31, 2021
Promissory Notes (Details) [Line Items]
Maturity date	Sep. 14, 2019	Sep. 11, 2019	Sep. 29, 2019	Dec. 31, 2019		Dec. 31, 2019
Number of warrants purchase (in Shares)	12,500
Strike price (in Dollars per share)	$ 1.25
Warrant expiration period	3 years
Warrants shares (in Shares)					2,643,635		1,175,000
Warrants					$ 471,825		$ 912,489
Promissory Note [Member]
Promissory Notes (Details) [Line Items]
Borrowed amount	$ 25,000	$ 25,000	$ 25,000	$ 20,000		$ 15,000
Debt default interest rate	5%	5%	5%			4%
Common stock shares converted (in Shares)					13,334
Number of warrants purchase (in Shares)		12,500	12,500
Strike price (in Dollars per share)		$ 1.25	$ 1.25
Warrant expiration period		3 years	3 years

Income Taxes (Details)

Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Taxes [Abstract]
Net operating loss carry forwards	$ 4,393,785
Federal statutory tax rate	21%
Increase valuation allowance	$ 0
Net operating loss	221,827
Provision for income taxes	$ 0	$ 0

Stockholders' Deficit (Details)

Stockholders' Deficit (Details) - USD ($)										1 Months Ended				3 Months Ended		6 Months Ended	12 Months Ended
	Nov. 06, 2022	Nov. 06, 2020	Nov. 01, 2020	Dec. 01, 2019	Jul. 02, 2019	Apr. 01, 2019	Jan. 04, 2019	Aug. 13, 2018	Feb. 28, 2018	Oct. 26, 2020	Aug. 28, 2019	Sep. 30, 2018	Dec. 31, 2017	Dec. 31, 2021	Mar. 31, 2021	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Oct. 01, 2021	Jul. 31, 2021	Dec. 22, 2020	Feb. 23, 2018
Stockholders' Deficit (Details) [Line Items]
Common stock, shares authorized														100,000,000			100,000,000	100,000,000
Common stock, par value (in Dollars per share)														$ 0.0001			$ 0.0001	$ 0.0001
Preferred stock, shares authorized														5,000,000			5,000,000	5,000,000
Preferred stock, par value (in Dollars per share)														$ 0.0001			$ 0.0001	$ 0.0001
Aggregate of shares		321,489																				218,000
Shares issued for services rendered					79,672	95,050	115,050				600,000
Price per share (in Dollars per share)													$ 2
Sold shares								16,000
Shares of common stock (in Dollars)								$ 20,000
Shares of restricted common stock required to be issued									400
Per share issued for service (in Dollars per share)							$ 1.25
Restricted shares				250,000
Description of AVRA issued an aggregate		On November 6, 2020, AVRA issued an aggregate 256,027 Units (“Units”) at a price of $1.00 per Unit in a private offering (the “Offering”) to four “accredited investors.” Each Unit consisted of (a) four shares of our common stock (“Shares”); (b) a three-year warrant to purchase five Shares at an exercise price of $0.40 per Share; and (c) a 0.00008749_% limited liability company membership interest in Avra Air, LLC (“Avra Air”), a development stage company, which interest may be put to the Company at the option of the investor for a period of two years from issuance, in exchange for one Share. As a result of the foregoing, the investors were issued an aggregate of 1,024,108 Shares, warrants to purchase 1,280,135 Shares and a 22.4% limited liability company membership interest in Avra Air, LLC.
Received a commitment to sell units										135,000
Commitment to sell units amount (in Dollars)										$ 135,000
Promissory note (in Dollars)										25,000
Accrued interest (in Dollars)										$ 1,027
Commitment units										26,027
Shares for a stock option exercised	21,000
Exercise price per share (in Dollars per share)	$ 0.1
Shares of common stock																		1,810,800
Common stock shares issued														37,848,905			37,848,905	25,721,971	174,553
Conversion of Stock, Shares Issued														3,619,817	102,500	378,378
Issuance of common stock																				629,375
Common Stock [Member]
Stockholders' Deficit (Details) [Line Items]
Shares issued for services rendered
Common stock voting rights, description																	Holders are entitled to one vote for each share of common stock.
Minimum [Member]
Stockholders' Deficit (Details) [Line Items]
Per share issued for service (in Dollars per share)					$ 1.25	$ 1.25					$ 1.25			$ 0.13	$ 0.89	$ 0.89	$ 0.13
Maximum [Member]
Stockholders' Deficit (Details) [Line Items]
Per share issued for service (in Dollars per share)					$ 2.76	$ 2.41					$ 2			$ 0.89	$ 1.07	$ 1.02	$ 0.89
Chief Executive Officer [Member]
Stockholders' Deficit (Details) [Line Items]
Converted of notes payable (in Dollars)																		$ 302,700
Director Arthur Tomassetti [Member]
Stockholders' Deficit (Details) [Line Items]
Shares issued for services rendered		10,000
Seven Consultants, Advisors, and Service Providers [Member]
Stockholders' Deficit (Details) [Line Items]
Shares issued for services rendered			220,489
Farhan Taghizadeh, M.D., AVRA’s Chief Medical Officer [Member]
Stockholders' Deficit (Details) [Line Items]
Shares issued for services rendered			70,000
Avra Air, LLC [Member]
Stockholders' Deficit (Details) [Line Items]
Common stock shares issued																					472,222
Chief Medical Officers [Member]
Stockholders' Deficit (Details) [Line Items]
Common stock shares issued																			25,000
Six Consultants and Service Providers [Member]
Stockholders' Deficit (Details) [Line Items]
Shares issued for services rendered													150,000
Price per share (in Dollars per share)													$ 1.25
Shares of restricted common stock required to be issued												128,300
Farhan Taghizadeh [Member]
Stockholders' Deficit (Details) [Line Items]
Shares issued for services rendered													35,000
Price per share (in Dollars per share)													$ 1.25
Barry F. Cohen [Member]
Stockholders' Deficit (Details) [Line Items]
Shares issued for services rendered													19,500
A. Christian Schauer [Member]
Stockholders' Deficit (Details) [Line Items]
Shares issued for services rendered													13,500

2016 Incentive Stock Plan (Deta

2016 Incentive Stock Plan (Details) - USD ($)															12 Months Ended
	Nov. 06, 2022	Oct. 01, 2021	Jan. 26, 2021	Dec. 22, 2020	Oct. 26, 2020	Dec. 01, 2019	Oct. 01, 2019	Aug. 01, 2019	Apr. 01, 2019	Feb. 01, 2019	Jul. 01, 2018	May 01, 2018	Mar. 31, 2018	Oct. 01, 2017	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Aug. 01, 2016
2016 Incentive Stock Plan (Details) [Line Items]
Share issued during the period, value (in Dollars)																$ 170,000
Exercise price (in Dollars per share)	$ 0.1
Stock based compensation (in Dollars)															$ 767,237	$ 434,180
2016 Incentive Stock Plan [Member]
2016 Incentive Stock Plan (Details) [Line Items]
Shares of common stock (in Shares)								10,000,000											3,000,000
Expected volatility			106.16%	71.79%	44.35%
Risk-free interest rate			2%	2%	2%										2%
Expected dividend yield				2%			0%
Exercise price per share (in Dollars per share)		$ 0.25	$ 0.4	$ 0.25	$ 0.4
Shares issued (in Shares)		1,500,000									75,000
Share issued during the period, value (in Dollars)											$ 21,000
Option expiration date											Jul. 01, 2023
Option exercised (in Shares)																	210,000	0
Shares forfeited (in Dollars per share)													$ 97,639
Shareholder options purchased (in Shares)						750,000
Exercise price (in Dollars per share)						$ 1
Option expire						5 years
Number of shares vested (in Shares)																4,327,167	3,276,667
Share options issued, description															All options issued to-date expire after five years from the issue date. Except for the option for 1,779,000 shares issued to the CEO and to the Company’s counsel for 40,000 shares that vested immediately, all the options issued to date vest over three years.
Unrecognized compensation cost (in Dollars)															$ 94,955
Non-vested options recognized period															33 months
Expiring term															Sep. 30, 2024
Warrants granted per share (in Dollars per share)			$ 0.98	0.468	$ 0.4
Fair market value per share (in Dollars per share)				$ 0.468
Options [Member]
2016 Incentive Stock Plan (Details) [Line Items]
Expected volatility						61.91%	48.57%	62.43%	48.52%	50.58%	31.34%	62.16%		45.07%
Expected term											3 years	3 years		3 years
Risk-free interest rate						2%	2%	2%	2%	2%	2%	2%		2%
Expected dividend yield						0%		0%	0%	0%	0%	0%		0%
Exercise price per share (in Dollars per share)							$ 2		$ 1.25	$ 2	$ 1.25	$ 1.25		$ 1.25
Granted term						3yrs	3yrs	3yrs	3yrs	3yrs
Options [Member] | 2016 Incentive Stock Plan [Member]
2016 Incentive Stock Plan (Details) [Line Items]
Expected volatility											31.34%	62.16%
Expected term											3 years	3 years
Risk-free interest rate											2%	2%
Expected dividend yield											0%	0%
Exercise price per share (in Dollars per share)											$ 1.25	$ 1.25
Independent Directors [ Member} | 2016 Incentive Stock Plan [Member]
2016 Incentive Stock Plan (Details) [Line Items]
Exercise price per share (in Dollars per share)		$ 0.25
Shares issued (in Shares)		50,000
Chief Medical Officer [Member] | 2016 Incentive Stock Plan [Member]
2016 Incentive Stock Plan (Details) [Line Items]
Exercise price per share (in Dollars per share)		$ 0.25
Shares issued (in Shares)		350,000
Board of Directors Chairman [Member] | 2016 Incentive Stock Plan [Member]
2016 Incentive Stock Plan (Details) [Line Items]
Exercise price per share (in Dollars per share)		$ 0.25
Shares issued (in Shares)		390,000
Counsel for Services [Member] | 2016 Incentive Stock Plan [Member]
2016 Incentive Stock Plan (Details) [Line Items]
Exercise price per share (in Dollars per share)											$ 1.25
General and Administrative Expense [Member] | 2016 Incentive Stock Plan [Member]
2016 Incentive Stock Plan (Details) [Line Items]
Stock based compensation (in Dollars)															$ 159,949	$ 412,788

Commitments (Details)

Commitments (Details) - USD ($)

1 Months Ended

12 Months Ended

Sep. 07, 2022

Jul. 01, 2020

Aug. 01, 2019

Jul. 01, 2019

Jan. 01, 2019

Aug. 01, 2018

May 01, 2018

Mar. 01, 2018

Aug. 01, 2016

Jul. 16, 2016

Jul. 01, 2016

Jul. 31, 2021

Jan. 02, 2021

May 30, 2020

Apr. 30, 2020

Dec. 31, 2021

Dec. 31, 2019

Commitments (Details) [Line Items]

Employment agreements, description

On August 1, 2016, the Company entered into a three-year Employment Agreement with its Vice President of Global Business Development. The agreement provides for an annual salary of $96,000 per year, increasing to $144,000 per year beginning July 2017. Through December 2016, the employee agreed to not receive the compensation in cash until the Board of Directors deemed it prudent to pay some or all of his salary. Further the Agreement provides that the employee will receive a three-year option to purchase 300,000 shares of the Company’s common stock at an exercise price of $0.10 per share, with 100,000 shares vested on each yearly anniversary.

Expire date

May 01, 2023

Options exercisable (in Dollars per share)

$ 1.25

Restricted common shares (in Shares)

52,000

1,000,000

Employee agreement term

48 months

Employee’s base salary

$ 15,000

Vehicle expenses

$ 500

Exercise price (in Dollars per share)

$ 0.25

Lease payments

$ 2,223

$ 1,829.25

Lease expense

$ 2,454.75

$ 1,474.17

$ 1,964.74

Lease agreement percentage

50%

50%

Intellectual Property [Member]

Commitments (Details) [Line Items]

Extend funding value

163,307

Ownership amount

$ 43,548

Impairment loss amount

$ 43,548

Research funds value

$ 68,952

Royalty payment percentage

1%

Intellectual property exceeds

$ 20,000,000

Employment Agreements [Member]

Commitments (Details) [Line Items]

Shares stock award (in Shares)

300,000

Installments shares (in Shares)

60,000

Options shares vest (in Shares)

250,000

Vest date

3 years

Whereby compensation

$ 1,500

Restricted common shares (in Shares)

36,000

Chief Executive Officer [Member]

Commitments (Details) [Line Items]

Employment agreements, description

On July 1, 2016, the Company entered into an Employment Agreement with its Chairman and Chief Executive Officer. The agreement provides for an annual salary of $120,000 per year, increasing to $180,000 per year beginning July 2017. Through December 2016, the employee agreed to not receive the compensation in cash until the Board of Directors deemed it prudent to pay some or all of his salary. Further the Agreement provides that the employee will receive a three-year option to purchase 1,000,000 shares of the Company’s common stock at an exercise price of $0.10 per share, and becoming fully vested on August 15, 2016.

Shares fully vested (in Shares)

1,000,000

Chief Financial Officer [Member]

Commitments (Details) [Line Items]

Employment agreements, description

On August 1, 2016, the Company entered into a one-year Employment Agreement with its Chief Financial Officer. The agreement provides for an annual salary of $108,000 per year. Through December 2016, the employee agreed to not receive the compensation in cash until the Board of Directors deemed it prudent to pay some or all of his salary. Further the Agreement provides that the employee will receive a three-year option to purchase 210,000 shares of the Company’s common stock at an exercise price of $0.10 per share, with 70,000 shares becoming fully vested upon each yearly anniversary. The options are to be surrendered and cancelled if the Agreement is terminated. The Agreement has expired but its compensation terms continue in effect as long as the employee remains employed by the Company.

Subsequent Events (Details)

Subsequent Events (Details)				1 Months Ended	12 Months Ended
	Sep. 07, 2022 USD ($) shares	Jul. 01, 2022 USD ($) $ / shares shares	Jul. 01, 2020 shares	Jul. 31, 2022 shares	Dec. 31, 2021 USD ($)	Sep. 30, 2022 USD ($) $ / shares shares	Aug. 31, 2022 USD ($) $ / shares shares	Jul. 25, 2022 shares
Subsequent Events (Details) [Line Items]
Principal amount (in Dollars) | $					$ 2
Issued discount					10%
Conversion amount (in Dollars) | $					$ 100,000,000
Convertible note ,description					In order to fund the Interim Financing, the Company offered and sold to two accredited investors, $1,000,000 and $100,000 one-year convertible promissory notes (the “Convertible Notes”). The Convertible Notes will have the same interest rate and payment terms as the Cardio Notes and otherwise be substantially similar to the Cardio Notes, provided, however, that the Convertible Notes do not have an original issue discount. Further, upon consummation of the Transaction (if and when it is consummated) the Convertible Notes will automatically convert into a number of AVRA Shares determined by dividing the principal amount of the Convertible Notes by $100 million and multiplying such number expressed as a percentage by the number of AVRA Shares issued to Dr. Srivastava and the other shareholders of the SSI Parties (if any) upon closing of the Transaction. The Company may offer and sell up to an aggregate principal amount of $5,000,000 in Convertible Notes in order to fund the Interim Financing.
Restricted shares	52,000		1,000,000
SSI Parties [Member]
Subsequent Events (Details) [Line Items]
Shareholders percentage					95%
Forecast [Member]
Subsequent Events (Details) [Line Items]
Paid amount (in Dollars) | $		$ 5,000
Common stock shares issued		40,000				1,631,000	1,000,000
Price per share (in Dollars per share) | $ / shares		$ 0.1
Number of investors				4
Common stock price per share (in Dollars per share) | $ / shares						$ 0.25	$ 0.25
Receiving proceeds (in Dollars) | $						$ 407,750	$ 250,000
Voting rights percentage	49.80%
Amount paid (in Dollars) | $	$ 26,000
2016 Incentive Stock Plan [Member] | Forecast [Member]
Subsequent Events (Details) [Line Items]
Shares issued								20,000,000
Patent attorney [Member] | Forecast [Member]
Subsequent Events (Details) [Line Items]
Common stock shares issued		27,250
Counsel [Member] | Forecast [Member]
Subsequent Events (Details) [Line Items]
Common stock shares issued		240,270
AVRA Medical Robotics Inc [Member] | SSI Parties [Member]
Subsequent Events (Details) [Line Items]
Shareholders percentage					5%
Consultant [Member] | Forecast [Member]
Subsequent Events (Details) [Line Items]
Common stock shares issued		2,520,000
CEO [Member] | Forecast [Member]
Subsequent Events (Details) [Line Items]
Common stock shares issued		5,400,000
Price per share (in Dollars per share) | $ / shares		$ 0.1
Chief Medical Officer [Member] | Forecast [Member]
Subsequent Events (Details) [Line Items]
Common stock shares issued		500,000
Price per share (in Dollars per share) | $ / shares		$ 0.1
Chief Strategy Officer [Member] | Forecast [Member]
Subsequent Events (Details) [Line Items]
Common stock shares issued		500,000
Price per share (in Dollars per share) | $ / shares		$ 0.1
Chief Strategy Officer [Member] | Forecast [Member]
Subsequent Events (Details) [Line Items]
Common stock shares issued		160,000
Stock award date		April 15, 2019
Consultant [Member] | Forecast [Member]
Subsequent Events (Details) [Line Items]
Common stock shares issued		569,747
Avra Air LLC [Member] | Forecast [Member]
Subsequent Events (Details) [Line Items]
Common stock shares issued				301,027
SSI Parties [Member]
Subsequent Events (Details) [Line Items]
Paid amount (in Dollars) | $					$ 990,000
Converted notes (in Dollars) | $					$ 1,000,000
Interest rate					7%
Discount rate percentage					10%
Accrued interest (in Dollars) | $					$ 100,000,000
Principal amount (in Dollars) | $					$ 5,000,000
Issued discount					6%
Conversion amount (in Dollars) | $					$ 250,000,000
SSI Parties [Member] | Note One [Member]
Subsequent Events (Details) [Line Items]
Converted notes (in Dollars) | $					$ 100,000